Abstract |
The in vitro and in vivo activities of a series of (2R,3R)-2-(2,4-difluorophenyl)-3-(substituted indazol-1-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol as potential antifungal agents are described. In particular, the analog 12j having 5-bromo substitution on the indazole ring exhibited significant antifungal activity against a variety of fungal cultures (Candida spp. and Aspergillus spp.). In addition, oral administration of 12j showed its excellent efficacy against Candida albicans in a murine infection model and the significantly improved survival rates of the infected mice.
|
Authors | Joon Seok Park, Kyung A Yu, Tae Hee Kang, Sunghoon Kim, Young-Ger Suh |
Journal | Bioorganic & medicinal chemistry letters
(Bioorg Med Chem Lett)
Vol. 17
Issue 12
Pg. 3486-90
(Jun 15 2007)
ISSN: 0960-894X [Print] England |
PMID | 17433670
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antifungal Agents
- Indazoles
- Triazoles
|
Topics |
- Administration, Oral
- Animals
- Antifungal Agents
(chemical synthesis, pharmacology, therapeutic use)
- Aspergillus
(drug effects, growth & development)
- Candida
(drug effects, growth & development)
- Disease Models, Animal
- Indazoles
(chemical synthesis, pharmacology, therapeutic use)
- Mice
- Microbial Sensitivity Tests
- Rats
- Stereoisomerism
- Triazoles
(chemical synthesis, pharmacology, therapeutic use)
|